Management of chronic lymphocytic leukemia: An update

Matthew Kaufman; Jian Li Campian; Kanti R. Rai

doi:10.1016/S1548-5315(11)70352-7

Management of chronic lymphocytic leukemia: An update

Matthew Kaufman, Jian Li Campian, Kanti R. Rai

Section of Medical Oncology

Research output: Contribution to journal › Review article › peer-review

Abstract

Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the Western world. It is often discovered on routine blood tests showing the presence of lymphocytosis. CLL has a variable course, with survival ranging from months to many years. In the past several years, discoveries of prognostic markers have helped predict the disease course. In terms of treatment, the emergence of purine analogs and monoclonal antibodies, such as rituximab (anti-CD20) and alemtuzumab (anti-CD52), has significantly changed the landscape of therapeutic options available for CLL.

Original language	English
Pages (from-to)	271-278
Number of pages	8
Journal	Community Oncology
Volume	6
Issue number	6
DOIs	https://doi.org/10.1016/S1548-5315(11)70352-7
State	Published - Jun 2009

Access to Document

10.1016/S1548-5315(11)70352-7

Cite this

@article{5be977f50712475d9bee53b2b3e065f8,

title = "Management of chronic lymphocytic leukemia: An update",

abstract = "Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the Western world. It is often discovered on routine blood tests showing the presence of lymphocytosis. CLL has a variable course, with survival ranging from months to many years. In the past several years, discoveries of prognostic markers have helped predict the disease course. In terms of treatment, the emergence of purine analogs and monoclonal antibodies, such as rituximab (anti-CD20) and alemtuzumab (anti-CD52), has significantly changed the landscape of therapeutic options available for CLL.",

author = "Matthew Kaufman and Campian, {Jian Li} and Rai, {Kanti R.}",

year = "2009",

month = jun,

doi = "10.1016/S1548-5315(11)70352-7",

language = "English",

volume = "6",

pages = "271--278",

journal = "Community Oncology",

issn = "1548-5315",

number = "6",

}

TY - JOUR

T1 - Management of chronic lymphocytic leukemia

T2 - An update

AU - Kaufman, Matthew

AU - Campian, Jian Li

AU - Rai, Kanti R.

PY - 2009/6

Y1 - 2009/6

N2 - Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the Western world. It is often discovered on routine blood tests showing the presence of lymphocytosis. CLL has a variable course, with survival ranging from months to many years. In the past several years, discoveries of prognostic markers have helped predict the disease course. In terms of treatment, the emergence of purine analogs and monoclonal antibodies, such as rituximab (anti-CD20) and alemtuzumab (anti-CD52), has significantly changed the landscape of therapeutic options available for CLL.

AB - Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the Western world. It is often discovered on routine blood tests showing the presence of lymphocytosis. CLL has a variable course, with survival ranging from months to many years. In the past several years, discoveries of prognostic markers have helped predict the disease course. In terms of treatment, the emergence of purine analogs and monoclonal antibodies, such as rituximab (anti-CD20) and alemtuzumab (anti-CD52), has significantly changed the landscape of therapeutic options available for CLL.

UR - http://www.scopus.com/inward/record.url?scp=67649268400&partnerID=8YFLogxK

U2 - 10.1016/S1548-5315(11)70352-7

DO - 10.1016/S1548-5315(11)70352-7

M3 - Review article

AN - SCOPUS:67649268400

SN - 1548-5315

VL - 6

SP - 271

EP - 278

JO - Community Oncology

JF - Community Oncology

IS - 6

ER -

Management of chronic lymphocytic leukemia: An update

Abstract

Access to Document

Other files and links

Fingerprint

Cite this